SCHEMBL862325

SCHEMBL862325

Cc1cc2ccccc2nc1Cl

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.59
KMT2A Q03164 1/20 0.55
PDE10A Q9Y233 1/20 0.55
ALDH1A1 P00352 5/20 0.52
MAPT P10636 3/20 0.52
HPGD P15428 2/20 0.52
GLA P06280 2/20 0.52
ACHE P22303 1/20 0.52
MBNL1 Q9NR56 1/20 0.49
KDM4E B2RXH2 5/20 0.48
GAA P10253 1/20 0.48
STAT3 P40763 1/20 0.48
NQO2 P16083 1/20 0.46
CYP1A2 P05177 3/20 0.45
L3MBTL1 Q9Y468 2/20 0.44
ALOX5 P09917 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
LMNA P02545 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL970862 0.98 TDP1 (0.57) TDP1KMT2APDE10AALDH1A1MAPT
SCHEMBL18820327 0.80 PDE10A (0.45) TDP1PDE10AALDH1A1HPGDCYP1A2
SCHEMBL29911341 0.77 KMT2A (0.59) TDP1KMT2APDE10AALDH1A1MAPT
SCHEMBL244868 0.77 KMT2A (0.59) TDP1KMT2APDE10AALDH1A1MAPT
SCHEMBL422035 0.77 ALDH1A1 (0.63) TDP1KMT2APDE10AALDH1A1MAPT
SCHEMBL30486684 0.77 ALDH1A1 (0.63) TDP1KMT2APDE10AALDH1A1MAPT
SCHEMBL22326435 0.77 PDE10A (0.77) TDP1KMT2APDE10AALDH1A1MAPT
SCHEMBL8302695 0.77 POLB (0.48) KMT2AALDH1A1MAPTHPGDKDM4E
SCHEMBL3835603 0.77 CYP1A2 (0.50) KMT2AALDH1A1MAPTKDM4ECYP1A2
SCHEMBL3835940 0.77 KMT2A (0.62) KMT2AALDH1A1MAPTKDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 320 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119285543-B Sulfonylation method of halogenated quinoline and aryl sulfonyl hydrazine 南京工业大学 2026-05-15 CN claimed
CN-119285543-A Sulfonylation method of halogenated quinoline and aryl sulfonyl hydrazine 南京工业大学 2025-01-10 CN claimed
CN-104507913-A Antiproliferative benzo[b]azepin-2-ones HOFFMANN LA ROCHE 2015-04-08 CN claimed
CN-104320972-A Herbicidal composition comprising uracil compound as active ingredient DONGBU FARM HANNONG CO LTD 2015-01-28 CN claimed
EP-1100797-B1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES PFIZER LTD (GB) 2003-02-26 EP claimed
US-6372736-B1 ENZYME INHIBITORS PFIZER INC 2002-04-16 US claimed
EP-1100797-A1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES Pfizer Limited (GB) 2001-05-23 EP claimed
WO-2000005232-A1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES PFIZER LIMITED (GB) 2000-02-03 WO claimed
CN-119285543-B Sulfonylation method of halogenated quinoline and aryl sulfonyl hydrazine 南京工业大学 2026-05-15 CN disclosed
US-12522595-B2 Bicyclic ether O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors BIOGEN MA INC. (US) 2026-01-13 US disclosed
US-20250282792-A1 GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO NEUROCRINE BIOSCIENCES, INC. 2025-09-11 US disclosed
CN-119285543-A Sulfonylation method of halogenated quinoline and aryl sulfonyl hydrazine 南京工业大学 2025-01-10 CN disclosed
US-20240343716-A1 COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING ABIVAX (FR) 2024-10-17 US disclosed
EP-4400172-A2 PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS Incyte Holdings Corporation (US) 2024-07-17 EP disclosed
EP-0385662-A2 Heterocycles with inhibitory activity of 5-lipoxygenase ZENECA LIMITED (GB) 1990-09-05 EP disclosed
US-4886805-A Novel aminoalkylthio derivatives of triazolopyridine or triazoloquinoline, the processes for their preparation, and drugs, useful especially as analgesics, in which they are present Centre D'Activite Et De Recherches Pharmaceutique Industrielle Biologique Medicale (FR) 1989-12-12 US disclosed
EP-0254623-A1 Aminoalkylthio triazolopyridine or triazoloquinoline derivatives, process for their preparation, medicaments containing them, particularly useful as antalgics LABORATOIRES UPSA (FR) 1988-01-27 EP disclosed
CN-86103997-A The preparation method of triazolyl quinoline derivative class 1987-12-30 CN disclosed
EP-0221947-A1 TRIAZOLYL QUINOLINE DERIVATIVES. ALKALOIDA VEGYESZETI GYAR (HU) 1987-05-20 EP disclosed
WO-1986006721-A1 TRIAZOLYL QUINOLINE DERIVATIVES ALKALOIDA VEGYÉSZETI GYÁR (HU) 1986-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250282792-A1 GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO GNRHR, GHRHR, LHCGR TDP1 2969/4885KMT2A 1468/4885PDE10A 538/4885
US-20240343716-A1 COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING RCOR1, NR3C1, NR5A1 TDP1 1459/4885KMT2A 1667/4885PDE10A 3850/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.